Laidlaw Capital Markets is pleased to Co-Manage Aldeyra Therapeutics $125,000,000 financing alongside Jefferies and SVB Leerink. Over $300 million raised together since 2014, helping fuel Aldeyra’s excellent execution in developing its pipeline and delivering results for patients and investors.

Read Article: Aldeyra Therapeutics, Inc. Announces Pricing of $125 Million Public Offering of Common Stock

From globenewswire.com:

Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing as well as recent scientific developments, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ: HOTH).

Read full article: Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19

The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has been a partner for years now and we are excited for their continued success.

Click the link below for additional information:

iCAD Announces Closing of $25.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

From globenewswire.com:

Laidlaw Venture Partners (“LVP”), the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the successful closing of a $4 million Series A financing round for its portfolio company AerWave.

Click the link below for additional information:

AerWave Medical Closes Series A Financing

From globenewswire.com:

Voltron Therapeutics, Inc. today announced that it has appointed life science veteran Anthony Zook Executive Chairman of its Board of Directors.

As a global industry leader, Mr. Zook brings years of strategic experience to Voltron Therapeutics and is expected to be instrumental in the further development and eventual commercialization of its Self Assembling Vaccine (SAV) platform, and products such as the Covid-19 vaccine, HaloVax™ and cancer immunotherapy.

Read full article: Laidlaw Venture Partners Portfolio Company Voltron Therapeutics, Inc. Names Anthony Zook, Former CEO of AstraZeneca North America, Executive Chairman (globenewswire.com)

Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a partner for years now and we are excited for their continued progress as a commercial stage company.

https://evokepharmainc.gcs-web.com/news-releases/news-release-details/evoke-pharma-announces-pricing-public-offering-common-stock-0